1. Introduction {#sec1}
===============

Nontuberculous mycobacteria (NTM) are widely distributed in nature \[[@B2]\] and are opportunistic pathogens that can cause various diseases in multiple organs in humans and animals. Recently, the prevalence of NTM diseases has been on the rise \[[@B3], [@B4]\], and they are now recognized as representing an emerging public health problem \[[@B5]\].

*Mycobacterium abscessus* and*Mycobacterium fortuitum* are the most important RGMs (rapidly growing mycobacteria), with the former accounting for 80% of chronic pulmonary diseases caused by all RGM \[[@B6]\] and the latter being the main RGM responsible for extra-pulmonary disease, especially in cutaneous and plastic surgery-related infections \[[@B7]\].

*M. abscessus*is an opportunistic pathogen, which can cause human to human infection \[[@B8]\] and nosocomial infection \[[@B9]\]. It was reported to cause multiple community outbreaks of cutaneous infection by means of wading pool or swimming pool \[[@B10]--[@B12]\]. In addition,*M. abscessus* is one of the most severe drug resistant bacteria among the RGM \[[@B7], [@B14]\] and is therefore very difficult to treat \[[@B6], [@B13]\]. In order to achieve the goal of 12-month sputum conversion on medication, it is essential to guide treatment regimens based on drug susceptibility results \[[@B15]\].

*M. fortuitum* can often cause soft tissue infection during trauma and surgery. It had also been reported in many implant-associated infections \[[@B16]\] and in endocarditis infections \[[@B16], [@B17]\]. It was reported susceptible to multiple drugs except for macrolides \[[@B18]\]. However, the antibiotics resistance spectrum varies with different geographic locations or different hospital administration situation.

In this study, we investigated the drug susceptibility status of 30 commonly used antibiotics among 37 clinical isolates of*M. abscessus* and*M. fortuitum*. In addition, we compared the drug susceptibility results with those of other studies worldwide to provide a clearer picture of the current antibiotic resistance levels for these two common RGM species, which could serve as valuable reference data to guide treatment.

2. Methods {#sec2}
==========

2.1. Strains and Antibiotics {#sec2.1}
----------------------------

In total, 20*M. abscessus* and 17*M. fortuitum* isolates were collected from various clinical specimens, including 23 sputum isolates, 5 bronchoalveolar lavage isolates, 2 puncture fluid isolates, 2 tissue isolates, 2 urine isolates, 1 wound isolate, 1 cerebrospinal fluid isolate, and 1 exudate isolate, from patients at the Huashan Hospital affiliated to Fudan University between January 2009 and December 2013. All isolates were from unique patients, except that one isolate of*M. abcessus* and*M. fortuitum* were cultured from two specimens of the same patient. All 37 isolates were recovered in Mueller-Hinton Broth (Oxoid, Hampshire, UK).*M. abscessus* ATCC19977 and*M. fortuitum* ATCC6841 were used as the reference strains.*Mycobacterium peregrinum* ATCC700686 was used as the quality control strain in drug susceptibility tests.

Rifampin, ethambutol, streptomycin, kanamycin, amikacin, ethionamide, clarithromycin, doxycycline, imipenem, linezolid, tobramycin, clindamycin, sulfamethoxazole, clofazimine, minocycline, neomycin, tetracycline, gentamycin, and vancomycin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Isoniazid, levofloxacin, moxifloxacin, rifabutin, cefoxitin, ciprofloxacin, and oxacillin were purchased from Fluka/Sigma-Aldrich (St. Louis, MO, USA). Azithromycin, tigecycline, teicoplanin, and cefmetazole were purchased from Aladdin (Shanghai, China), Calbiochem/Sigma-Aldrich (St. Louis, MO, USA), Bio Vision (CA, USA), and Meilunbio (Dalian, China), respectively.

2.2. Subspecies Identification among M. abscessus Complex Isolates {#sec2.2}
------------------------------------------------------------------

Isolates were thawed and recovered on Lowenstein-Jensen medium at 37°C or on BACTER MGIT 960 medium for 4--7 days. DNA was extracted from cultured colonies using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) in accordance with the manufacturer\'s protocol and used as templates for polymerase chain reaction (PCR). The*rrs* gene \[[@B19]\] was amplified with primers*rrs*-F (5′-AGTTTGATCCTGGCTCAG) and*rrs*-R (5′-GGTTACCTTGTTACGACTT) and*hsp65*\[[@B22], [@B21], [@B20], [@B23]\] was amplified with primers*hsp*-F (5′-CGATGCGGTAAAGGTGACATTG) and*hsp*-R (5′-CCTTGACAGTGGACACCTTGGA). PCR was carried out in a final volume of 50 *μ*l with 1 *μ*l of DNA supernatant containing approximately 10 ng of genomic DNA, 5 *μ*l of 10× ExTaq PCR Buffer, 4 *μ*l of dNTPs (2.5 mM each), 0.4 *μ*M of each primer, 0.5 *μ*l of ExTaq DNA Polymerase (5 U/*μ*l) (Takara, Japan), and 37.5 *μ*l of distilled water. DNA samples were first denatured completely by incubation at 95°C for 5 min and then amplified using 35 cycles of (i) denaturation at 95°C for 40 s, (ii) primer annealing at 58°C for 40 s, and (iii) elongation at 72°C for 1 min in a thermocycler. The PCR products were sequenced by the Sanger method. Consensus sequences for each isolate were assembled using Lasergene SeqMan II software (DNAStar, Inc., Madison, WI, USA).

2.3. Drug Susceptibility Testing {#sec2.3}
--------------------------------

The susceptibility tests of all 37 isolates and the reference*M. peregrinum* ATCC700686 against 30 antibiotics were carried out by the broth microdilution method in 96-well plates (Nunc, Denmark) according to the Clinical and Laboratory Standards Institute (CLSI) guidelines M24- A2. \[[@B24]\]. The final drug concentrations tested are shown in [Table 1](#tab1){ref-type="table"}. The minimum inhibitory concentrations (MICs) of all antibiotics except for clarithromycin were determined after 3 days of incubation at 37°C. For clarithromycin, the incubation process lasted for 14 days. The MIC was determined as the lowest concentration of the drug that resulted in no visible bacterial growth. MIC90 values were defined as drug concentrations that inhibited 90% of the isolates. The susceptibility was determined based on CLSI breakpoint recommendations and published studies ([Table 2](#tab2){ref-type="table"}). The resistance rates comparison between*M. abscessus*subsp.*abscessus* and*M. abscessus* subsp.*massiliense* was statistically analyzed by Fisher\'s exact chi-square test. A p-value of \< 0.05 indicated statistical significance.

3. Results {#sec3}
==========

3.1. Species Identification {#sec3.1}
---------------------------

There were 17 isolates identified as*M. fortuitum* and 20 isolates identified as*M. abscessus.* Among 20*M. abscessus*isolates, 12 isolates were classified as*M. abscessus*subsp.*abscessus*, 7 isolates were classified as*M. abscessus* subsp.*massiliense*, and one isolate was classified as*M. abscessus* subsp.*bolletii* based on their*hsp65* gene.

3.2. Resistance to Antitubercular Drugs {#sec3.2}
---------------------------------------

Both*M. abscessus* and*M. fortuitum* were highly resistant to antitubercular drugs such as isoniazid, rifampin, ethambutol, clofazimine, ethionamide, and rifabutin. Specifically, all isolates (100%) were resistant to isoniazid, ethambutol, and rifampin ([Table 1](#tab1){ref-type="table"}). All of the*M. abscessus* isolates (100%) and 16 of the 17 (94%)*M. fortuitum* isolates were resistant to both ethionamide and rifabutin. Only one*M. abscessus* subsp.*abscessus* isolate and 7 of 17 (41%)*M. fortuitum* isolates were susceptible to clofazimine. This result reconfirmed that first-line antitubercular drugs are not useful for treating infections by*M. abscessus* or*M. fortuitum*. In addition, in order to better investigate the susceptibility of second-line antitubercular drugs to these strains, such as clofazimine, linezolid, and kanamycin, the first-line antitubercular drugs were partially used as a control in the study.

3.3. Resistance of M. abscessus to Non-Antitubercular Antibiotics {#sec3.3}
-----------------------------------------------------------------

In general, the antibiotic resistance rates of the 20*M. abscessus* isolates were very high. All or almost all isolates were resistant to sulfamethoxazole, vancomycin, oxacillin, clindamycin, and all fluoroquinolones, and more than 50% of the isolates were resistant to tetracyclines, carbapenems, and aminoglycosides except for amikacin ([Table 1](#tab1){ref-type="table"}).*M. abscessus* showed the lowest resistance rates to cefoxitin (10%), azithromycin (10%), amikacin (10%), and clarithromycin (20%). For clarithromycin, the 14-day inducible resistance rate is 15% (3/20). There was no statistically difference in the resistance rates between*M. abscessus* subsp.*abscessus* and subsp.*massiliense* isolates except to minocycline, in which the latter subspecies showed less resistance ([Table 1](#tab1){ref-type="table"}).

3.4. Resistance of M. fortuitum to Non-Antitubercular Antibiotics {#sec3.4}
-----------------------------------------------------------------

Although macrolides and cefoxitin are important component of the treatment regimen for RGM, the results showed that 16 (94%), 17 (100%), and 15 (88%)*M. fortuitum* isolates were resistant to clarithromycin, azithromycin, and cefoxitin, respectively. Besides macrolides, all or almost all of the*M. fortuitum* isolates were resistant to kanamycin (94%), doxycycline (82%), minocycline (82%), vancomycin (100%), teicoplanin (100%), oxacillin (100%), and clindamycin (100%).*M. fortuitum* showed the lowest levels of resistance to tigecycline (0%), tetracycline (0%), cefmetazole (12%), imipenem (12%), linezolid (18%), and the aminoglycosides, including amikacin (0%), tobramycin (0%), neomycin (0%), and gentamycin (24%) ([Table 1](#tab1){ref-type="table"}). Isolates of*M. fortuitum* showed intermediate resistance rates to fluoroquinolones, which are also commonly considered in RGM treatment regimens. The resistance rates to moxifloxacin, ciprofloxacin, and levofloxacin were 59%, 47%, and 41%, respectively ([Table 1](#tab1){ref-type="table"}). Importantly, the isolates showed variable resistance to three tetracyclines, tigecycline, and two cephalosporins. They were mostly resistant to doxycycline, minocycline, and cefoxitin but were susceptible to tigecycline and cefmetazole.

4. Discussion {#sec4}
=============

Although the role of*in vitro* drug susceptibility testing has not been validated for most NTM species, these tests may nevertheless be important in the management of NTM-related diseases \[[@B21]\]. The need for long-term antibiotic treatment and associated toxicities contribute to the frequent unsatisfactory treatment outcomes in patients, thereby posing a great challenge to physicians in choosing the optimal regimen for patients infected with RGM. The present results of antibiotic susceptibility tests of the 30 most commonly used antibiotics against 37 RGM isolates, including subspecies of the*M. abscessus* complex isolates, supported the current recommendation of using amikacin, cefoxitin, and macrolides to treat*M. abscessus* infections \[[@B15]\]. Among the macrolides, azithromycin appears to be a better choice for treating*M. abscessus* infections than clarithromycin, since the susceptibility rate was lower for clarithromycin and the inducible resistance rate is 15%(3/20).

All*M. abscessus* isolates were resistant to streptomycin in our study (100%), which was in agreement with previous study \[[@B25]\]. However, in a study in Japan \[[@B26]\], the resistance rate to streptomycin was only 61%, which indicated the variance of the resistance in different healthcare background. For other rarely used aminoglycosides like tobramycin, neomycin, kanamycin, and gentamycin, the resistance rates of*M. abscessus* were also very high. The resistance rate to tobramycin was 60% in this study, which is higher than those of studies in Taiwan province of China \[[@B27]\], Korea \[[@B28]\], and Japan \[[@B26]\], in which the resistance rate varies from 30% to 32%. Broad spectrum antibiotics like minocycline, doxycycline, and sulfamethoxazole were ineffective against*M. abscessus* isolates; for their resistance rates reached 70%, 80%, and 90%, respectively. A recent study by Ruth et al. \[[@B29]\] proposed that minocycline has no clear roles in the treatment of*M. abscessus* disease, because of their high MICs against minocycline, rapid emergence of drug resistance, and no synergy effect with other antibiotics used to treat*M. abscessus*. Therefore, these antibiotics should not be used in clinics against*M. abscessus* infections.

Treatment with linezolid also appears to be a potentially good choice for this bacillus. The major difference between*M. abscessus* subsp.*abscessus* and*M. abscessus* subsp.*massiliense* is that the former has an innate*erm*(41) gene that confers the ability for inducible macrolide resistance; therefore, precise differentiation between these subspecies has been proposed to be important for clinical purposes \[[@B23], [@B30]\]. Our study showed that the macrolides resistance rate of*M. abscessus* subsp.*abscessus* was higher than that of*M. abscessus* subsp.*massiliense*, but the difference was not statistically significant due to the limitation of isolate numbers, which was consistent with the results conducted by Nie et al. \[[@B23]\]. However, except for macrolides and minocycline, differentiation between these two subspecies could not provide additional drug resistance information, as their resistance profiles were largely similar. In addition, the results of our study indicate that two commonly used drugs, macrolides and cefoxitin, should not be used in the treatment of*M. fortuitum* infection, since the isolates showed high resistance rates to both drugs. Given the lower resistance rates, aminoglycosides, cefmetazole, tigecycline, imipenem, and linezolid are potentially good choices for treatment regimens against*M. fortuitum* infection.

When the drug resistance rates obtained in the present study were compared with those reported previously, we found that high resistance to multiple antimicrobials was mostly prevalent in*M. abscessus*. Almost all studies indicated that*M. abscessus* isolates are highly susceptible to amikacin, cefoxitin, and macrolides and low resistance to linezolid ([Table 3](#tab3){ref-type="table"}). By contrast, the imipenem data varied markedly among studies. The present study and those conducted in 2016 in Shanghai \[[@B31]\], 2017 in Taiwan \[[@B32]\], and 2015 in Australia \[[@B33]\] showed high resistance of*M. abscessus*to imipenem, whereas studies conducted in 2017 in Korea \[[@B34]\], 2013 in Guangdong \[[@B35]\], 2014 in Beijing \[[@B5]\], 2008 in Korea \[[@B28]\], and 2003 in Taiwan \[[@B27]\] showed relatively lower resistance rates to imipenem. Most studies did not support the use of fluoroquinolones and doxycycline, except for tigecycline ([Table 3](#tab3){ref-type="table"}).

Although the drug resistance of*M. fortuitum* does not appear to be as prevalent as that of*M. abscessus*, the resistance rates to multiple antibiotics, including sulfamethoxazole, linezolid, clarithromycin, cefoxitin, and tobramycin, vary extensively among studies ([Table 4](#tab4){ref-type="table"}). In addition, except for the present study, amikacin was reported to show the most effective*in vitro* activity in all previous studies. Most studies recommended the use of imipenem, except for the study conducted in 2017 in Guangzhou \[[@B37]\], in the treatment of*M. fortuitum* infection ([Table 4](#tab4){ref-type="table"}). Low to medium degrees of fluoroquinolones resistance were observed in*M. fortuitum*in the majority of studies, in which moxifloxacin resistance varied from 0% to 59% and ciprofloxacin resistance varied from 3% to 47% ([Table 4](#tab4){ref-type="table"}). The variability of susceptibility to different antimicrobials among studies emphasizes the importance of drug susceptibility testing in cases of*M. fortuitum* infection. The antibiotic susceptibility variance may be due to the difference in the choices of DST methods and breakpoints.

For some rarely used antibiotics applied in*M. fortuitum* treatment like neomycin and tigecycline, the susceptibility rates were 100% and 94% separately, suggesting they are very prospective antibiotics in the treatment. For gentamycin, although the susceptibility was only 24%, the intermediate rate was as high as 52%, which should be used in cautions in high doses.

Among the 36 patients, 29 were hospitalized and had detailed record of hospitalization. Among them, 27 have empirical antibiotic treatment, including meropenem, levofloxacin, clarithromycin, and rifampin, before the diagnosis of NTM associated diseases. Only 2 patients had no history of antibiotics treatment. Mostly patients had empirical anti-infection therapy in the hospital which could be the reason of the generally higher resistance rates in these isolates.

Nevertheless, this study has several limitations that should be mentioned. First, the isolates were geographically limited to a single province. Second, there was a limited number of RGM isolates collected, because of the relatively low incidence of RGM infections in Shanghai. Consequently, the power for detecting resistance to multiple antibiotics could be reduced in terms of generalizability to other RGM isolates worldwide.

In conclusion, the present results showed that amikacin, cefoxitin, and azithromycin had the highest*in vitro* activity against*M. abscessus*, which is in line with current recommendations. However, in contrast to previous studies,*M. fortuitum* was found to be mostly resistant to macrolides and cefoxitin. Therefore, isolates of*M. fortuitum* should be individually evaluated with the drug susceptibility test in deciding the most effective antimicrobials for treatment of infections.
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###### 

The drug susceptibility results of 37 RGM isolates.

  Antimicrobial Agent   MIC(*μ*g/ml)   *M. abscessus* (n=20)   MIC(*μ*g/ml)     *M. fortuitum* (n=17)                                                                             
  --------------------- -------------- ----------------------- ---------------- ----------------------- ------------------ ----------- ------ ------------------- --------------- --------------
  Macrolides                                                                                                                                                                       
   CLR                  0.0625-64      32                      4 (20%)/7(35%)   0 (0%)/0 (0%)           16 (80%)/13(65%)   32-64       32     16 (94%)/17(100%)   0 (0%)/0 (0%)   1 (6%)/0(0%)
   AZM                  0.125-128      2                       2 (10%)          0 (0%)                  18 (90%)           8-128       32     17 (100%)           0 (0%)          0 (0%)
  Rifamycins                                                                                                                                                                       
   RFB                  0.5-8          4                       15 (75%)         \-                      5 (25%)            1-8         4      16 (94%)            \-              1 (6%)
   RIF                  64-256         128                     20 (100%)        \-                      0 (0%)             32-256      128    17 (100%)           \-              0 (0%)
  Aminoglycosides                                                                                                                                                                  
   STR                  32-128         64                      20 (100%)        \-                      0 (0%)             16-128      32     17 (100%)           \-              0 (0%)
   GEN                  0.5-64         32                      14 (70%)         1 (5%)                  5 (25%)            4-64        32     4 (24%)             9 (53%)         4 (24%)
   KAN                  4-16           8                       16 (80%)         \-                      4 (20%)            4-32        16     16 (94%)            \-              1 (6%)
   TOB                  2-32           8                       12 (60%)         3 (15%)                 5 (25%)            16-64       16     0 (0%)              0 (0%)          17 (100%)
   NEO                  0.5-64         16                      13 (65%)         \-                      7 (35%)            2-8         2      0 (0%)              \-              17 (100%)
   AMK                  0.5-64         32                      2 (10%)          9 (45%)                 9 (45%)            2-8         4      0 (0%)              0 (0%)          17 (100%)
  Fluoroquinolones                                                                                                                                                                 
   MXF                  0.0625-16      8                       19 (95%)         0 (0%)                  1 (5%)             0.0625-8    2      10 (59%)            5 (29%)         2 (12%)
   CIP                  0.125-128      64                      19 (95%)         0 (0%)                  1 (5%)             0.125-256   128    8 (47%)             0 (0%)          9 (53%)
   LVX                  0.125-32       16                      19 (95%)         0 (0%)                  1 (5%)             0.125-32    16     7 (41%)             0 (0%)          10 (59%)
  Cephalosporins                                                                                                                                                                   
   FOX                  16-256         64                      2 (10%)          10 (50%)                8 (40%)            16-128      32     15 (88%)            0 (0%)          2 (12%)
   CMZ                  2-256          128                     11 (55%)         5 (25%)                 4 (20%)            2-64        8      2 (12%)             0 (0%)          15 (88%)
  Tetracyclines                                                                                                                                                                    
   TCY                  2-256          64                      9 (45%)          3 (15%)                 8 (40%)            1-8         4      0 (0%)              12 (70%)        5 (30%)
   DOX                  0.5-256        128                     14 (70%)         2 (10%)                 4 (20%)            0.5-256     128    15 (88%)            0 (0%)          2 (12%)
   MNO                  0.125-128      64                      11 (55%)         3 (15%)                 6 (30%)            0.25-32     16     14 (82%)            1 (6%)          2 (12%)
  Glycylcycline                                                                                                                                                                    
   TGC                  0.0625-16      8                       8 (40%)          6 (30%)                 6 (30%)            0.0625-4    0.5    0 (0%)              1 (6%)          16 (94%)
  Sulfonamides                                                                                                                                                                     
   SOX                  2-256          128                     18 (90%)         \-                      2 (10%)            16-256      128    14 (82%)            \-              3 (18%)
  Carbapenems                                                                                                                                                                      
   IMP                  1-256          64                      13 (65%)         2 (10%)                 5 (25%)            2-32        16     2 (12%)             12 (70%)        3 (18%)
  Oxazolidinones                                                                                                                                                                   
   LNZ                  2-128          16                      3 (15%)          1 (5%)                  16 (80%)           8-32        16     3 (18%)             12 (70%)        2 (12%)
  Lincosamides                                                                                                                                                                     
   CLI                  8-256          128                     20 (100%)        0 (0%)                  0 (0%)             256         256    17 (100%)           0 (0%)          0 (0%)
  Penicillins                                                                                                                                                                      
   OXA                  256            256                     20 (100%)        \-                      0 (0%)             256         256    17 (100%)           \-              0 (0%)
  Polypeptides                                                                                                                                                                     
   TEC                  0.5-256        128                     17 (85%)         1 (5%)                  2 (10%)            128-256     128    17 (100%)           0 (0%)          0 (0%)
   VAN                  256            256                     20 (100%)        0 (0%)                  0 (0%)             256         256    17 (100%)           0 (0%)          0 (0%)
  Others                                                                                                                                                                           
   CFZ                  0.25-128       32                      19 (95%)         \-                      1 (5%)             0.125-128   0.25   10 (59%)            \-              7 (41%)
   EMB                  256            256                     20 (100%)        \-                      0 (0%)             256         256    17 (100%)           \-              0 (0%)
   INH                  8-256          16                      20 (100%)        \-                      0 (0%)             8-16        8      17 (100%)           \-              0 (0%)
   ETH                  16-256         64                      20 (100%)        \-                      0 (0%)             4-256       32     16 (94%)            \-              1 (6%)

\(a\) CLR= clarithromycin, AZM= azithromycin, RFB= rifabutin, RIF= rifampin, STR= streptomycin, GEN= gentamycin, KAN= kanamycin, TOB= tobramycin, NEO= neomycin, AMK= amikacin, MXF= moxifloxacin, CIP= ciprofloxacin, LVX= levofloxacin, FOX= cefoxitin, CMZ= cefmetazole, TCY= tetracycline, DOX= doxycycline, MNO= minocycline, TGC= tigecycline, SOX= sulfamethoxazole, IMP= imipenem, LNZ= linezolid, CLI= clindamycin, OXA= oxacillin, TEC= teicoplanin, VAN= vancomycin, CFZ= clofazimine, EMB= ethambutol, INH= isoniazid, and ETH= ethionamide.

\(b\) "-" indicates data not available.

\(c\) For CLR, each resistance and susceptible rate has two data. The first is the MIC result for 3 days and the second is the MIC result for 14 days.

###### 

Breakpoints of 30 antibiotics.

  Antimicrobial Agent   MIC breakpoints (*μ*g/ml)                    
  --------------------- --------------------------- -------- ------- --------
  *Macrolides*          CLR^a^                      ⩽2       4       *⩾*8
                        AZM^c^                      ⩽2       4       *⩾*8
  *Rifamycins*          RIF^a^                      \-       \-      \>1
                        RFB^a^                      \-       \-      \>2
  *Aminoglycosides*     STR^a^                      \-       \-      *⩾*5
                        GEN^b^                      \<=4     8       \>=16
                        KAN^a^                      \-       \-      *⩾*4
                        TOB^a^                      ⩽2       4       *⩾*8
                        NEO^b^                      \-       \-      \>=10
                        AMK^a^                      ⩽16      32      *⩾*64
  *Fluoroquinolones*    MXF^a^                      ⩽1       2       *⩾*4
                        CIP^a^                      ⩽1       2       *⩾*4
                        LVX^a^                      ⩽2       4       *⩾*8
  *Cephalosporin*       FOX^a^                      ⩽16      32-64   *⩾*128
                        CMZ^d^                      ⩽16      32      *⩾*64
  *Tetracyclines*       TCY^b^                      \<=4     8       \>=16
                        DOX^a^                      ⩽1       2-4     *⩾*8
                        MNO^a^                      ⩽1       2-4     *⩾*8
  *Glycylcycline*       TGC^a^                      ⩽1       2-4     *⩾*8
  *Sulfonamides*        SOX^a^                      ⩽38      \-      *⩾*76
  *Carbapenems*         IMP^a^                      ⩽4       8-16    *⩾*32
  *Oxazolidinones*      LNZ^a^                      ⩽8       16      *⩾*32
  *Lincosamides*        CLI^b^                      \<=0.5   1-2     \>=4
  *Penicillins*         OXA^b^                      \<=2     \-      \>=4
  *Polypeptides*        TEC^b^                      \<=8     16      \>=32
                        VAN^b^                      \<=2     4-8     \>=16
  Others                CFZ^e^                      \-       \-      \>1
                        INH^a^                      \-       \-      *⩾*1
                        EMB^a^                      \-       \-      *⩾*4
                        ETH^a^                      \-       \-      \>5

a denotes the breakpoints coming from **Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard--Second Edition**. *CLSI document M24-A2*.

b denotes the breakpoints coming from Performance Standards Antimicrobial Susceptibility Testing-27th Edition.*CLSI document M100*.

c, d, e denote the breakpoints coming from \[[@B22]--[@B39]\], respectively.

d, S, susceptible, I, intermediate susceptible, and R, resistant.

###### 

The comparison of drug resistance rate of *M*. *abscessus*isolates from various studies.

  district/nation   year   Test method   Tetracyclines   Glycylcycline   Carbapenems                                      Aminoglycosides   Fluoroquinolones   Macrolides   source                                                                                        
  ----------------- ------ ------------- --------------- --------------- ------------- ---------- ----------- ----------- ----------------- ------------------ ------------ ----------- ----------- ----------- ----------- ---------- ---------- ----------- ----------- ------------
  Shanghai          2017   1             14 (70%)        11 (55%)        8 (40%)       13 (65%)   \-          3 (15%)     18 (90%)          2 (10%)            2 (10%)      12 (60%)    20 (100%)   19 (95%)    19 (95%)    19 (95%)   \-         9 (45%)     2 (10%)     This study
  Taiwan            2017   1             66 (99%)        66 (99%)        \-            41 (61%)   \-          47 (70%)    60 (90%)          14 (21%)           4 (6%)       \-          \-          60 (90%)    63 (94%)    \-         5 (7%)     19 (28%)    \-          \[[@B32]\]
  Korea             2017   1             \-              \-              \-            17 (18%)   \-          5 (5%)      \-                10 (10%)           6 (6%)       \-          \-          94 (99%)    88 (93%)    \-         9 (9%)     39 (41%)    \-          \[[@B34]\]
  Beijing           2016   1             \-              \-              4 (18%)       9 (41%)    \-          2 (9%)      10 (45%)          7 (32%)            1 (5%)       8 (36%)     \-          \-          6 (27%)     17 (77%)   3 (14%)    \-          17 (77%)    \[[@B40]\]
  Shanghai          2016   1             52 (98%)        \-              \-            52 (98%)   \-          11 (21%)    \-                15 (28%)           1 (2%)       44 (83%)    \-          \-          51 (96%)    \-         15 (28%)   36 (68%)    \-          \[[@B31]\]
  UK                2015   2             \-              \-              3 (1%)        \-         534 (99%)   311 (96%)   \-                531 (96%)          74 (14%)     \-          \-          495 (99%)   257 (98%)   \-         33 (6%)    \-          191 (38%)   \[[@B41]\]
  Fujian et al.     2015   1             36 (65%)        31 (56%)        2 (4%)        \-         16 (29%)    2 (4%)      \-                17 (31%)           0 (0%)       30 (55%)    52 (95%)    31 (56%)    12 (22%)    29 (53%)   18 (33%)   \-          12 (22%)    \[[@B25]\]
  Singapore         2015   1             235 (80%)       \-              \-            50 (20%)   \-          50 (16%)    95 (94%)          8 (3%)             1 (0.9%)     282 (98%)   \-          293 (94%)   115 (93%)   \-         11 (3%)    \-          \-          \[[@B42]\]
  Australia         2015   1             32 (84%)        \-              \-            26 (68%)   \-          7 (18%)     35 (92%)          7 (18%)            2 (5%)       22 (58%)    \-          36 (95%)    35 (92%)    \-         \-         18 (47%)    \-          \[[@B33]\]
  Beijing           2014   1             \-              \-              \-            7 (10%)    \-          2 (3%)      \-                1 (1%)             1 (1%)       \-          \-          \-          10 (14%)    68 (97%)   22 (31%)   38 (54%)    3 (4%)      \[[@B5]\]
  Korea             2014   1             \-              \-              \-            \-         \-          \-          \-                \-                 40 (10%)     \-          \-          361 (89%)   319 (79%)   \-         64 (16%)   186 (46%)   \-          \[[@B43]\]
  Japan             2013   1             139 (97%)       119 (83%)       73 (51%)      34 (24%)   \-          16 (11%)    143(100%)         \-                 7 (5%)       44 (31%)    87 (61%)    137 (96%)   135 (94%)   \-         18 (13%)   \-          \-          \[[@B26]\]
  Guangdong         2013   1             \-              \-              \-            15 (21%)   \-          \-          \-                3 (4%)             0 (0%)       \-          \-          56 (80%)    \-          \-         10 (14%)   \-          \-          \[[@B35]\]
  Korea             2008   1             60 (81%)        \-              \-            8 (11%)    \-          \-          \-                0 (0%)             0 (0%)       22 (30%)    \-          13 (18%)    5 (7%)      \-         2 (3%)     \-          \-          \[[@B28]\]
  Taiwan            2003   1             85 (92%)        \-              \-            17 (10%)   91 (99%)    39 (42%)    91 (99%)          4 (4%)             4 (4%)       28 (32%)    \-          87 (96%)    75 (82%)    88 (96%)   10 (11%)   \-          44 (48%)    \[[@B27]\]

\(1\) 1 means broth microdilution method and 2 means disc diffusion method.

\(2\) "-" means the results are not available.

\(3\) SXT=trimethoprim-sulfamethoxazole. SXT and SOX have the same mainly effective ingredient sulfamethoxazole, so we compare the results together.

###### 

The comparison of drug resistance rate of *M. fortuitum* isolates from various studies.

  district/nation   year   Test method   Aminoglycosides               Fluoroquinolones                         Carbapenems              Sulfonamides   source                           
  ----------------- ------ ------------- ----------------- ----------- ------------------ ---------- ---------- ------------- ---------- -------------- ---------- ---------- ---------- ------------
  Shanghai          2017   1             0 (0%)            0 (0%)      15 (88%)           10 (59%)   8 (47%)    17 (100%)     15 (88%)   2 (12%)        \-         3 (18%)    14 (82%)   This study
  Guangzhou         2017   1             7 (14%)           51 (100%)   \-                 2 (4%)     21 (41%)   39 (76%)      \-         29 (57%)       13 (25%)   43 (84%)   \-         \[[@B37]\]
  Mumbai            2016   2             0 (0%)            0 (0%)      22 (100%)          \-         5 (23%)    0 (0%)        \-         4 (18%)        \-         0 (0%)     21 (95%)   \[[@B44]\]
  India             2016   1             0 (0%)            \-          \-                 \-         5 (24%)    3 (14%)       \-         \-             \-         \-         \-         \[[@B45]\]
  Iran              2016   1             1 (2%)            0 (0%)      8 (14%)            25 (29%)   12(14%)    \-            36 (42%)   8 (9%)         42 (49%)   6 (7%)     0 (0%)     \[[@B46]\]
  Singapore         2015   1             3 (3%)            73 (92%)    7 (8%)             0 (0%)     3 (3%)     44 (47%)      \-         3 (3%)                    6 (7%)     1 (3%)     \[[@B42]\]
  Taiwan            2003   1             0 (0%)            32 (46%)    1 (1%)             17 (25%)   23(33%)    14 (20%)      47 (68%)   5 (7%)         28 (41%)   17 (25%)   35 (51%)   \[[@B27]\]

\(1\) 1 means broth microdilution method and 2 means disc diffusion method.

\(2\) "-" means the results are not available.

\(3\) SXT=trimethoprim-sulfamethoxazole. SXT and SOX have the same mainly effective ingredient sulfamethoxazole, so we compare the results together.

[^1]: Academic Editor: Paola Di Carlo
